Intelligence Feed event · Equity · 2026-09-19

    Twist Bioscience partners with Eli Lilly on AI-driven TuneLab drug discovery

    Question

    Twist Bioscience partners with Eli Lilly on AI-driven TuneLab drug discovery

    Direct answer

    Twist Bioscience announced an agreement to integrate its antibody discovery and characterization services into Eli Lilly's TuneLab computational platform. The stock gained more than 31 percent on the week. Under the terms, Twist will supply high-throughput antibody data generated through its AbLab model to accelerate AI-driven lead candidate optimization. This expands Twist's biopharma service monetization beyond standard gene synthesis.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-19
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Twist Bioscience partners with Eli Lilly on AI-driven TuneLab drug discovery”, revision 1, evidence through 2026-09-19. https://marketontology.com/market-events/2026-09-19/twist-bioscience-partners-with-eli-lilly-on-ai-driven-tunelab-drug-discovery-3c6cb9

    EQUITY
    Twist Bioscience partners with Eli Lilly on AI-driven TuneLab drug discovery
    Twist Bioscience announced an agreement to integrate its antibody discovery and characterization services into Eli Lilly's TuneLab computational platform. The stock gained more than 31 percent on the week. Under the terms, Twist will supply high-throughput antibody data generated through its AbLab model to accelerate AI-driven lead candidate optimization. This expands Twist's biopharma service monetization beyond standard gene synthesis.
    TWSTLLY
    Impact
    75
    SEP 19
    SIG
    92%
    TWSTLLY
    Twist Bioscience partners with Eli Lilly on AI-driven TuneLab drug discovery
    Twist Bioscience announced an agreement to integrate its antibody discovery and characterization services into Eli Lilly's TuneLab computational platform. The stock gained more than 31 percent on the week. Under the terms, Twist will supply high-throughput antibody data generated through its AbLab model to accelerate AI-driven lead candidate optimization. This expands Twist's biopharma service monetization beyond standard gene synthesis.
    → Pharma computational biology partnerships generate milestone and licensing revenue flows while validating synthetic biology platforms.
    Impact
    Twist Bioscience announced an agreement to integrate its antibody discovery and characterization services into Eli Lilly's TuneLab computational platform. The stock gained more than 31 percent on the week. Under the terms, Twist will supply high-throughput antibody data generated through its AbLab model to accelerate AI-driven lead candidate optimization. This expands Twist's biopharma service monetization beyond standard gene synthesis.
    Affected
    TWSTLLY
    Transmission
    Pharma computational biology partnerships generate milestone and licensing revenue flows while validating synthetic biology platforms.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    TWSTbiopharma technology licensing and data services revenue growthUp1-4wShares rose over 31% on partnership disclosure with Eli Lilly.
    LLYAI-assisted pipeline candidate discovery efficiencyWatch1-3mIncorporation of AbLab models into proprietary TuneLab platform.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month